What should a nurse monitor in a patient receiving griseofulvin therapy?

Griseofulvin is an antifungal medication used primarily to treat dermatophyte infections of the skin, hair, and nails. A critical aspect of monitoring a patient receiving griseofulvin therapy is observing liver function tests. This is due to the potential for hepatic toxicity associated with the medication. Griseofulvin is metabolized in the liver, and its use can lead to alterations in liver function, particularly in patients with preexisting liver conditions.

Monitoring liver function tests includes assessing levels of enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as well as bilirubin levels. Any significant elevation in these tests could indicate hepatotoxicity, prompting immediate medical evaluation and potentially discontinuation of the medication.

While monitoring electrolyte levels, kidney function tests, and blood glucose levels may be relevant in other clinical scenarios or with different medications, they are not as critical in the context of griseofulvin treatment. Therefore, the correct focus for monitoring in patients on griseofulvin is primarily on liver function tests to ensure safe and effective management of the therapy.